Given both the regulatory influence of JAM-A on breast cancer cell migration in vitro and its link with metastasis in patient tissue samples [19], our studies suggest a role for JAM-A as a potentially important therapeutic target for the development of future breast cancer therapies. The gene discussed is F11R; the disease is breast carcinoma.